Trevena

TRVN NASDAQ
0.9120
+0.0294
+3.33%
Closed 16:00 08/19 EDT
Open
0.8819
Prev Close
0.8826
High
0.9350
Low
0.8787
Volume
300.39K
Avg Vol (3M)
673.14K
52 Week High
3.578
52 Week Low
0.3823
% Turnover
0.32%
Market Cap
84.42M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Trevena TRVN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
MORE >

Recently

Name
Price
%Change